Immatics N.V. (NASDAQ:IMTX – Get Free Report) Director Perceptive Advisors Llc bought 863,060 shares of Immatics stock in a transaction on Wednesday, August 26th. The shares were purchased at an average price of $8.69 per share, for a total transaction of $7,499,991.40. Following the acquisition, the director directly owned 11,246,516 shares in the company, valued at approximately $97,732,224.04. This trade represents a 8.31% increase in their position. The acquisition was disclosed in a document filed with the SEC, which is available at this hyperlink.
Immatics Stock Up 1.0%
IMTX opened at $9.45 on Friday. Immatics N.V. has a 52 week low of $5.05 and a 52 week high of $12.41. The stock has a market cap of $1.27 billion, a PE ratio of -5.08 and a beta of 1.33. The business has a 50 day moving average of $9.44 and a 200-day moving average of $10.03.
Immatics (NASDAQ:IMTX – Get Free Report) last posted its quarterly earnings data on Tuesday, August 18th. The company reported ($0.53) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.47) by ($0.06). Immatics had a negative return on equity of 47.41% and a negative net margin of 495.71%.The firm had revenue of $10.44 million during the quarter, compared to the consensus estimate of $12.42 million. Equities analysts anticipate that Immatics N.V. will post -2 EPS for the current year.
Institutional Trading of Immatics
Wall Street Analyst Weigh In
IMTX has been the topic of a number of analyst reports. Jefferies Financial Group set a $17.00 price target on Immatics in a research report on Tuesday. Wall Street Zen downgraded Immatics from a “hold” rating to a “sell” rating in a report on Saturday, May 2nd. Chardan Capital reissued a “buy” rating and issued a $25.00 target price on shares of Immatics in a research note on Tuesday, May 19th. Finally, Weiss Ratings downgraded Immatics from a “sell (d)” rating to a “sell (d-)” rating in a report on Tuesday, June 23rd. Six equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, Immatics has a consensus rating of “Moderate Buy” and a consensus target price of $20.60.
Check Out Our Latest Research Report on Immatics
Immatics Company Profile
Immatics N.V. (NASDAQ: IMTX) is a clinical-stage biotechnology company dedicated to the development of T cell receptor (TCR)-based immunotherapies for solid tumors. The company leverages its proprietary discovery and engineering platforms to identify tumor-specific peptide targets and develop therapies that harness the power of a patient’s immune system. Immatics’ approach aims to generate durable responses by guiding T cells to recognize and kill cancer cells with high precision.
At the core of Immatics’ technology suite is the XPRESIDENT® platform, which mines the cancer peptidome to uncover novel tumor antigens naturally presented on the surface of cancer cells.
Featured Articles
- Five stocks we like better than Immatics
- From SaaS-pocalypse to Perfect Storm: Workday’s AI Growth Story Strengthens
- These 3 GARP Stocks Show Why Growth and Value Do Not Have to Clash
- Venture Into High-Volatility Corners of the Market With These 3 ETFs
- 3 Retail Stocks to Watch After a Big Consumer Earnings Week
Receive News & Ratings for Immatics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immatics and related companies with MarketBeat.com's FREE daily email newsletter.
